0/541991 JC12 Rec'd PCT/FT

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO **Application Number** Not Yet Assigned Filing Date INFORMATION DISCLOSURE Herewith - July 5, 2005 First Named Inventor Mohammad R. Marzabadi STATEMENT BY APPLICANT Art Unit Not Yet Assigned **Examiner Name** Not Yet Assigned (Use as many sheets as necessary) Attorney Docket Number 65369-US-PCT1

3

Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind Code ^{2 (d known)}			Figures Appear
		US- 6,727,264	04/27/2004	Marzabadi, et al.	
		^{US-} 6,441,000	08/27/2002	Gibson, et al.	
		^{US-} 5,459,151	10/17/1995	. Lombardo	
		^{US-} 2004/0186103	09/23/2004	Marzabadi, et al.	
		US- 2004/0073036	04/15/2004	Marzabadi, et al.	
		^{US-} 2004/0038855	02/26/2004	Salon, et al.	
		US- 2003/0077701	04/24/2003	Salon, et al.	
		^{US-} 10/719,358	Not Yet Published	Marzabadi, et al.	
		US-			
		US			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	_
Initials*	No.'	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁵
•		′ WO 04/058727	07/15/2004	Bayer Pharmaceuticals	·	
		/ WO 04/005257	01/15/2004	Synaptic Pharmaceutical		
***************************************		, WO 04/004714	01/15/2004	Synaptic Pharmaceutical		
***************************************		. WO 03/004027	01/16/2003	Synaptic Pharmaceutical	***************************************	
	1	, WO 02/094799	11/28/2002	Neurogen	•••••••••••••••••••••••••••••••••••••••	

Examiner	 	Date	
Signature	•	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10/541991 JC12 Rec'd PCT/PTC 0 5 JUL 2005

Approved for use through 07/31/2006. OMB 0651-0031 ark Office: U.S. DEPARTMENT OF COMMERCE

· Under the Paperwork Reduction Act of 1995, no persons are required Substitute for form 1449A/PTO	Complete if Known		
	Application Number	Not Yet Assigned	
INFORMATION DISCLOSURE	Filing Date	Herewith - July 5, 2005	
STATEMENT BY APPLICANT	First Named Inventor	Mohammad R. Marzabadi	
STATEMENT BY ALL EIGHT	Art Unit	Not Yet Assigned	
(Use as many sheets as necessary)	Examiner Name	Not Yet Assigned	
Sheet 2 of 3	Attorney Docket Number	65369-US-PCT1	

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	
Initials*	No.1		MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
		Number-Kind Code ^{2 (d known)}			Figures Appear	
		US-				
		US-			•	
		US-			,	
····	<u> </u>	US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-		,	-	
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,		
Initials*	No.'	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY Applicant of Cited Docume	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	™	
		, WO 02/030927	04/18/2002	Pierre Fabre Medicament	· · · · · · · · · · · · · · · · · · ·		
	<u> </u>	✓ WO 02/006245	01/24/2002	Synaptic Pharmaceutical			
	Ī	7 WO 02/002744	01/10/2002	Synaptic Pharmaceutical			
		✓ WO 00/021934	04/20/2000	Astra Zeneca	***************************************		
	1					m	

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98: The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10/541991 JC12 Rec'd PCT/PTC 05 JUL 2005

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

DTO.		e required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
FIO		Application Number	Not Yet Assigned		
ON DIS	CLOSURE	Filing Date	Herewith - July 5, 2005		
STATEMENT BY APPLICANT			Mohammad R. Marzabadi		
abasta as a		Art Unit	Not Yet Assigned		
ny sneets as ne	eessary)	Examiner Name	Not Yet Assigned		
of	3	Attorney Docket Number	65369-US-PCT1		
	T BY A	ON DISCLOSURE T BY APPLICANT ny sheets as necessary)	Application Number Filing Date T BY APPLICANT First Named Inventor Art Unit Examiner Name	Application Number Not Yet Assigned Filing Date Herewith - July 5, 2005 T BY APPLICANT First Named Inventor Mohammad R. Marzabadi Art Unit Not Yet Assigned Examiner Name Not Yet Assigned Atterney Decket Number Proceedings of the point of the poin	

		NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
	TAKEKAWA, S., et al., "T-226296: a novel, orally active and selective melanin-concentrating hormone receptor antagonist", European Journal of Pharmacology, March 2002, 438, pp. 129-135							
			l ly					
:								
			·					
:								

Examiner		Date	
Signature		Considered	
*EVAMINED: In	itial if reference accordanced whether are not citation in in and	The state of the s	71-11

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.